A Subject-Blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of UCB7665 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2015
Price : $35 *
At a glance
- Drugs Rozanolixizumab (Primary) ; Rozanolixizumab (Primary)
- Indications Immunological disorders
- Focus Adverse reactions; First in man
- Sponsors UCB
- 02 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 01 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 01 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.